Foghorn to discontinue independent development of FHD-286 with decitabine in AML

Foghorn Therapeutics (FHTX) has made the decision to discontinue the independent development of FHD-286 in combination with decitabine in patients with relapsed and/or refractory acute myeloid leukemia. Foghorn is evaluating partnerships and ISTs to advance FHD-286. The Company will prioritize its proprietary pipeline and Lilly (LLY) collaboration programs, including the clinical-stage selective SMARCA2 inhibitor FHD-909. As of September 30, 2024, the Company had $267.4M in cash, cash equivalents and marketable securities. Its cash runway supports the Company into 2027. In the Phase 1 dose escalation trial of FHD-286 in combination with decitabine in relapsed and/or refractory AML, objective clinical responses were observed by standard response criteria. However, the observed response rate did not meet the Company’s threshold to continue development by Foghorn alone. Foghorn expects to report the results at a medical conference in 2025. “While clinical responses were observed for FHD-286, we will prioritize investment into our proprietary pipeline, including our Selective CBP program, Selective EP300 program, and ARID1B program, as well as our Lilly collaboration, including the clinical development of FHD-909.” said Adrian Gottschalk, CEO. “Our pipeline of potential medicines represents significant opportunities in oncology with the potential for therapeutic expansion. We want to thank the clinical investigators, the patients, and their families for their participation in the FHD-286 clinical trial.”